Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer

Next Previous
Trial Profile

A Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Neratinib (Primary) ; Paclitaxel; Trastuzumab
  • Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms NEFERTT
  • Sponsors Puma Biotechnology; Wyeth Pharmaceuticals

Most Recent Events

  • 14 Dec 2019 Primary endpoint has not been met. (Progression-Free Survival)
  • 14 Dec 2019 Results of pooled analysis from the NALA, NEfERT-T, and TBCRC 022 trials, assessing Impact of neratinib on development and progression of central nervous system (CNS) metastases in patients with HER2-positive metastatic breast cancer, presented at the 42nd Annual San Antonio Breast Cancer Symposium
  • 08 Feb 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top